GlaxoSmithKline Pakistan Limited reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was PKR 13,770.54 million compared to PKR 11,925.66 million a year ago. Net loss was PKR 69.79 million compared to net income of PKR 148.66 million a year ago. Basic loss per share from continuing operations was PKR 0.22 compared to basic earnings per share from continuing operations of PKR 0.47 a year ago.
For the nine months, sales was PKR 37,029.87 million compared to PKR 30,094 million a year ago. Net loss was PKR 391.62 million compared to net income of PKR 779.88 million a year ago. Basic loss per share from continuing operations was PKR 1.23 compared to basic earnings per share from continuing operations of PKR 2.45 a year ago.